US Bancorp’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,221
| Closed | -$485 | – | 4224 |
|
|
2023
Q3 | $485 | Hold |
1,221
| – | – | ﹤0.01% | 3849 |
|
|
2023
Q2 | $842 | Hold |
1,221
| – | – | ﹤0.01% | 3827 |
|
|
2023
Q1 | $9.63K | Hold |
1,221
| – | – | ﹤0.01% | 3297 |
|
|
2022
Q4 | $1.1K | Hold |
1,221
| – | – | ﹤0.01% | 3910 |
|
|
2022
Q3 | $1K | Hold |
1,221
| – | – | ﹤0.01% | 4049 |
|
|
2022
Q2 | $2K | Hold |
1,221
| – | – | ﹤0.01% | 3916 |
|
|
2022
Q1 | $3K | Hold |
1,221
| – | – | ﹤0.01% | 3793 |
|
|
2021
Q4 | $4K | Hold |
1,221
| – | – | ﹤0.01% | 3764 |
|
|
2021
Q3 | $5K | Hold |
1,221
| – | – | ﹤0.01% | 3683 |
|
|
2021
Q2 | $6K | Hold |
1,221
| – | – | ﹤0.01% | 3590 |
|
|
2021
Q1 | $6K | Hold |
1,221
| – | – | ﹤0.01% | 3472 |
|
|
2020
Q4 | $8K | Hold |
1,221
| – | – | ﹤0.01% | 3289 |
|
|
2020
Q3 | $12K | Hold |
1,221
| – | – | ﹤0.01% | 3036 |
|
|
2020
Q2 | $15K | Hold |
1,221
| – | – | ﹤0.01% | 2964 |
|
|
2020
Q1 | $13K | Hold |
1,221
| – | – | ﹤0.01% | 2952 |
|
|
2019
Q4 | $6K | Hold |
1,221
| – | – | ﹤0.01% | 3259 |
|
|
2019
Q3 | $9K | Hold |
1,221
| – | – | ﹤0.01% | 3109 |
|
|
2019
Q2 | $11K | Hold |
1,221
| – | – | ﹤0.01% | 3080 |
|
|
2019
Q1 | $12K | Hold |
1,221
| – | – | ﹤0.01% | 3021 |
|
|
2018
Q4 | $15K | Hold |
1,221
| – | – | ﹤0.01% | 2930 |
|
|
2018
Q3 | $20K | Buy |
+1,221
| New | +$29K | ﹤0.01% | 2929 |
|
Other funds holding BLPH
US Bancorp's BLPH Position: Q4 2023 in Review
US Bancorp sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 1,221 shares — an estimated $485 sold.
US Bancorp first reported a position in BLPH in Q3 2018 and held it in 21 quarters. The position peaked at $20K in Q3 2018. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.
- US Bancorp reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
- US Bancorp sold 1,221 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $485.
- US Bancorp first reported a position in Bellerophon Therapeutics, Inc. in Q3 2018 and held it in 21 quarters.
- US Bancorp's Bellerophon Therapeutics, Inc. position peaked at $20K in Q3 2018.
- 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.
Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.